New Tool Enables Scientists to Interpret “Dark Matter” DNA
Scientists at the Gladstone Institutes have invented a new way to read and interpret the human genome. The computational method, called TargetFinder, can predict where non-coding DNA—the DNA that does not code for proteins—interacts with genes. This technology helps researchers connect mutations in the so-called genomic “dark matter” with the genes they affect, potentially revealing new therapeutic targets for genetic disorders.
In the study, published in Nature Genetics, the researchers looked at fragments of non-coding DNA called enhancers. Enhancers act like an instruction manual for a gene, dictating when and where a gene is turned on. Genes can be separated from their enhancers by long stretches of DNA that contain many other genes.
“Most genetic mutations that are associated with disease occur in enhancers, making them an incredibly important area of study,” said senior author Katherine Pollard, PhD, a senior investigator at the Gladstone Institutes. “Before now, we struggled to understand how enhancers find the distant genes they act upon.”
Scientists originally believed that enhancers mostly affect the gene nearest to them. However, the new study revealed that, on a strand of DNA, enhancers can be millions of letters away from the gene they influence, skipping over the genes in between. When an enhancer is far away from the gene it affects, the two connect by forming a three-dimensional loop, like a bow on the genome.
Using machine learning technology, the researchers analyzed hundreds of existing datasets from six different cell types to look for patterns in the genome that identify where a gene and enhancer interact. They discovered several patterns that exist on the loops that connect enhancers to genes. This pattern accurately predicted whether a gene-enhancer interaction occurred 85 percent of the time.
“It’s remarkable that we can predict complex three-dimensional interactions from relatively simple data,” said first author Sean Whalen, PhD, a biostatistician at Gladstone. “No one had looked at the information stored on loops before, and we were surprised to discover how important that information is.”
Performing experiments in the lab to identify all of these gene-enhancer interactions can take millions of dollars and years of research. The new computational approach is a much cheaper and less time-consuming way to identify gene-enhancer connections in the genome. The technology also provides insight into how DNA loops form and how they might break in disease. The scientists have offered all of the code and data from TargetFinder online for free.
“Our ability to predict the gene targets of enhancers so accurately enables us to link mutations in enhancers to the genes they target,” said Pollard. “Having that link is the first step towards using these connections to treat diseases.
Up Next
Gladstone Scientists Are Awarded $2 Million to Map How HIV Affects the Immune System
By uniting the power of single-cell sequencing, organoids, and artificial intelligence, scientists are entering a new era of HIV research.
Christina Theodoris Honored in Inaugural Cohort of Young American Scientists
Scientific American recognizes Theodoris for her pioneering work developing artificial intelligence models to find treatments for an array of diseases.
How an AI Microscope Is Learning to Do Science
Gladstone scientists have developed a thinking microscope that can conduct its own experiments, with the ultimate goal of treating neurodegenerative diseases.
Gladstone Launches Center for PhAIge Therapy to Harness AI in the Fight Against Drug-Resistant Infections
The center, funded by an NIH grant, will become one of three national centers dedicated to accelerating the development of phage therapy.
Get Involved
Join the Team
Our people are our most important asset. We offer a wide array of career opportunities both in our administrative offices and in our labs.
Open PositionsPartner With Us
Discoveries don’t stay in our labs. Gladstone facilitates spinout companies to advance promising therapies, shortening the path between scientific discovery and helping real patients.
Learn MoreGive
Your gift to Gladstone will allow our researchers to pursue high-quality science, focus on disease, and train the next generation of scientific thought leaders.
Donate Now